JP2018521979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521979A5 JP2018521979A5 JP2017563092A JP2017563092A JP2018521979A5 JP 2018521979 A5 JP2018521979 A5 JP 2018521979A5 JP 2017563092 A JP2017563092 A JP 2017563092A JP 2017563092 A JP2017563092 A JP 2017563092A JP 2018521979 A5 JP2018521979 A5 JP 2018521979A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- prodrug
- compound
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170498P | 2015-06-03 | 2015-06-03 | |
| US62/170,498 | 2015-06-03 | ||
| US201562233081P | 2015-09-25 | 2015-09-25 | |
| US62/233,081 | 2015-09-25 | ||
| PCT/US2016/035721 WO2016196935A1 (en) | 2015-06-03 | 2016-06-03 | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020125200A Division JP2020169223A (ja) | 2015-06-03 | 2020-07-22 | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521979A JP2018521979A (ja) | 2018-08-09 |
| JP2018521979A5 true JP2018521979A5 (https=) | 2019-04-25 |
Family
ID=56133104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563092A Pending JP2018521979A (ja) | 2015-06-03 | 2016-06-03 | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
| JP2020125200A Pending JP2020169223A (ja) | 2015-06-03 | 2020-07-22 | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020125200A Pending JP2020169223A (ja) | 2015-06-03 | 2020-07-22 | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180140572A1 (https=) |
| EP (1) | EP3302462A1 (https=) |
| JP (2) | JP2018521979A (https=) |
| KR (1) | KR20180015195A (https=) |
| CN (1) | CN107847481A (https=) |
| AU (1) | AU2016271475A1 (https=) |
| BR (1) | BR112017026025A2 (https=) |
| CA (1) | CA2988126A1 (https=) |
| EA (1) | EA201792623A1 (https=) |
| HK (1) | HK1245632A1 (https=) |
| IL (1) | IL256052A (https=) |
| MX (1) | MX2017015618A (https=) |
| PH (1) | PH12017502195A1 (https=) |
| TW (1) | TW201717935A (https=) |
| WO (1) | WO2016196935A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050566B1 (en) | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2017132049A1 (en) * | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| KR20190103156A (ko) * | 2016-12-20 | 2019-09-04 | 에테하 취리히 | 암에서 비-유전적 약물 내성 프로그램을 표적으로 하는 약물의 동정 |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| WO2018160887A1 (en) * | 2017-03-01 | 2018-09-07 | Boston Biomedical, Inc. | Pdl1-specific and beta-catenin-specific asymmetric interfering rna compositions, uses or preparation thereof |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018232230A1 (en) * | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| EP3870161A1 (en) * | 2018-10-23 | 2021-09-01 | Université catholique de Louvain | Guanabenz as an adjuvant for immunotherapy |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| EP3714883A1 (en) * | 2019-03-25 | 2020-09-30 | AC BioScience SA | Indole containing small chemical compounds and use thereof for the non-cytotoxic and immunological treatment of cancer |
| CN113891709A (zh) * | 2019-04-02 | 2022-01-04 | 德克萨斯大学系统董事会 | 用于治疗疾病的转录抑制剂和免疫检验点抑制剂的组合 |
| JPWO2021039616A1 (https=) * | 2019-08-23 | 2021-03-04 | ||
| EP4118238A4 (en) * | 2020-03-12 | 2024-04-17 | Personal Genome Diagnostics Inc. | MICROSATELLITE INSTABILITY SIGNATURES |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| EP1897540A3 (en) * | 1999-01-27 | 2008-07-23 | University Of South Florida | Inhibition of STAT3 signal transduction for human cancer therapy |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| EP2357009A1 (en) | 2002-07-15 | 2011-08-17 | Board of Regents, The University of Texas System | Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2005042581A2 (en) | 2003-11-01 | 2005-05-12 | Biovation Ltd. | Modified anti-cd52 antibody |
| EP2287195B1 (en) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US7951374B2 (en) * | 2004-12-14 | 2011-05-31 | University Of South Florida | Methods for inhibiting STAT3 signaling in immune cells |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20070009532A1 (en) | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| JP2010537640A (ja) | 2007-08-27 | 2010-12-09 | ボストン バイオメディカル， インコーポレイテッド | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
| EP3050566B1 (en) * | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2998405B1 (en) | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011084694A1 (en) * | 2009-12-17 | 2011-07-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Stabilized stat3 decoy oligonucleotides and uses therefor |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| RU2571661C2 (ru) | 2010-03-19 | 2015-12-20 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
| PT2547205T (pt) * | 2010-03-19 | 2024-05-27 | 1Globe Biomedical Co Ltd | Novos métodos para atingir células estaminais cancerígenas |
| EP2547205B1 (en) | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
| US9150530B2 (en) | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
| CN113967253A (zh) * | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| US10005752B2 (en) * | 2014-06-09 | 2018-06-26 | Kyoto Pharmaceutical Industries, Ltd. | Anticancer agent |
| WO2016030455A1 (en) | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
-
2016
- 2016-06-03 MX MX2017015618A patent/MX2017015618A/es unknown
- 2016-06-03 WO PCT/US2016/035721 patent/WO2016196935A1/en not_active Ceased
- 2016-06-03 AU AU2016271475A patent/AU2016271475A1/en not_active Abandoned
- 2016-06-03 KR KR1020177037893A patent/KR20180015195A/ko not_active Withdrawn
- 2016-06-03 HK HK18104905.6A patent/HK1245632A1/zh unknown
- 2016-06-03 CN CN201680037409.8A patent/CN107847481A/zh active Pending
- 2016-06-03 EA EA201792623A patent/EA201792623A1/ru unknown
- 2016-06-03 BR BR112017026025A patent/BR112017026025A2/pt not_active Application Discontinuation
- 2016-06-03 EP EP16729734.0A patent/EP3302462A1/en not_active Withdrawn
- 2016-06-03 JP JP2017563092A patent/JP2018521979A/ja active Pending
- 2016-06-03 TW TW105117553A patent/TW201717935A/zh unknown
- 2016-06-03 US US15/579,013 patent/US20180140572A1/en not_active Abandoned
- 2016-06-03 CA CA2988126A patent/CA2988126A1/en not_active Abandoned
-
2017
- 2017-12-01 PH PH12017502195A patent/PH12017502195A1/en unknown
- 2017-12-03 IL IL256052A patent/IL256052A/en unknown
-
2020
- 2020-07-22 JP JP2020125200A patent/JP2020169223A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521979A5 (https=) | ||
| Carneiro et al. | Emerging therapeutic targets in bladder cancer | |
| Shaw et al. | Targeting the Wnt signalling pathway in cancer: prospects and perils. | |
| JP2020169223A (ja) | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 | |
| ZA202110422B (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| RU2020124007A (ru) | Комбинированный препарат, включающий агонист tlr7 | |
| JP2017528524A5 (https=) | ||
| CA3133688A1 (en) | Compositions and methods for treating cancer | |
| Galluzzi et al. | Novel immune checkpoint blocker approved for the treatment of advanced melanoma | |
| Ladds et al. | Small molecule activators of the p53 response | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2021504399A5 (https=) | ||
| JP2023541432A (ja) | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 | |
| JP2025011315A5 (https=) | ||
| Ammannagari et al. | Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers | |
| EA039630B1 (ru) | N-замещенные индольные производные | |
| Zhou et al. | Combinatorial therapies in melanoma: MAPK inhibitors and beyond | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| JP2018514557A5 (https=) | ||
| JP2022500448A5 (https=) | ||
| AU2017271615A1 (en) | 6-thio-2'-deoxyguanosine (6-thio-dG) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells | |
| Haki et al. | Innovative approaches for molecular targeted therapy of breast cancer: interfering with various pathway signaling | |
| JP2018511642A5 (https=) |